We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Risk of NSAIDs May Be Overstated

By HospiMedica staff writers
Posted on 07 Sep 2005
A new epidemiologic study based on detailed patient surveys rather than administrative databases suggests not only that non-aspirin, nonsteroidal, anti-inflammatory drugs (NANSAIDs) that are inhibitors of cyclooxygenase (COX) may not harm patients but, on the contrary, may have a protective effect against heart attack.

Previous studies have shown that aspirin, a nonsteroidal anti-inflammatory drug (NSAID), reduces the risk of heart attack and stroke. More...
However, in the wake of problems found with some other COX inhibitors such as Vioxx, recent studies of NANSAIDs have shown an increased risk, some have shown no association between NANSAIDs and heart attack, and some have suggested a lower risk of heart attack.

The prior studies used prescription records from billing data or electronic databases. Then a February 2005 study by Stephen E. Kimmel, M.D., associate professor of medicine at the University of Pennsylvania and associate professor of epidemiology in the department of biostatics and epidemiology (Philadelphia, USA), suggested a benefit of nonselective NANSAIDS. In this study, data were collected from study participants instead of relying on limited information from electronic databases. The research showed that of all the nonsteroids used, 80% were over-the-counter drugs and mostly ibuprofen.

In the new study, participants were asked about their use of both prescription and over-the-counter nonsteroidal and aspirin use and about several risk factors for heart attacks that are typically unavailable or incomplete in administrative databases. When each category of bias was removed, NANSAIDs showed a stronger protective association with heart attack. The findings of the study were reported in the August 2005 issue of Pharmacoepidemiology and Drug Safety.

"As you add into the model more and more useful and relevant information, the association between nonsteroidals and heart attacks changes, and it changes in the direction of showing more benefit,” explained Dr. Kimmel. "We are not saying we know the whole answer, but our data suggest there might be beneficial effects of nonsteroidals and there are clearly limitations to interpreting the epidemiologic studies that are now out there.”

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.